Optic Nerve Sheath Diameter in Pre-Eclamptic Parturient Receiving Magnesium Sulfate Combined With Dexmedetomidine

Launched by BENHA UNIVERSITY · Nov 8, 2022

Keywords

ClinConnect Summary

This clinical trial is studying how a medication called dexmedetomidine affects the pressure inside the brain (intracranial pressure or ICP) in pregnant women who have severe pre-eclampsia. Pre-eclampsia is a serious condition that can occur during pregnancy, leading to high blood pressure and other health issues. The researchers want to determine if giving dexmedetomidine along with magnesium sulfate therapy can help manage the pressure in the optic nerve, which can be measured using a simple eye ultrasound.

To participate in this trial, women aged 18 to 40 who are at least 36 weeks pregnant and have been diagnosed with severe pre-eclampsia may be eligible. However, those with certain health issues, such as previous eye surgeries, chronic diseases, or specific complications related to pregnancy, cannot take part. Participants will receive the medications being studied and will be monitored closely to see how they respond. This research aims to improve care for women with severe pre-eclampsia and ensure safer outcomes for both mothers and their babies.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • aged18 to 40 years with
• • at least 36 weeks gestation
• • admitted with diagnosis of severe pre-eclampsia and scheduled to receive Magnesium Sulphate therapy before delivery
• Exclusion Criteria:
• • Presence of ocular wound or Prior ocular surgery
• • emergency cases, and evidence of fetal compromise
• • HELLP syndrome (hemolysis, elevated liver enzymes, and low platelet levels)
• • Chronic hypertension
• • Hyperthyroidism, and diabetes mellitus
• • Presence of pre-existing chronic lung and/or cardiac diseases
• • Presence of pre-existing chronic renal and/or hepatic diseases
• • Presence of any chronic diseases of central nervous system.
• • known allergies to the tested drug.